Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Prepaid Assets (2022 - 2025)

Historic Prepaid Assets for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $19.8 million.

  • Axsome Therapeutics' Prepaid Assets rose 4755.8% to $19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.8 million, marking a year-over-year increase of 4755.8%. This contributed to the annual value of $12.0 million for FY2024, which is 4760.32% up from last year.
  • Per Axsome Therapeutics' latest filing, its Prepaid Assets stood at $19.8 million for Q3 2025, which was up 4755.8% from $16.3 million recorded in Q2 2025.
  • Axsome Therapeutics' Prepaid Assets' 5-year high stood at $19.8 million during Q3 2025, with a 5-year trough of $2.1 million in Q1 2022.
  • Its 4-year average for Prepaid Assets is $9.3 million, with a median of $8.1 million in 2023.
  • As far as peak fluctuations go, Axsome Therapeutics' Prepaid Assets surged by 19180.15% in 2023, and later surged by 3303.69% in 2025.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Prepaid Assets stood at $2.8 million in 2022, then skyrocketed by 191.8% to $8.1 million in 2023, then skyrocketed by 47.6% to $12.0 million in 2024, then skyrocketed by 65.21% to $19.8 million in 2025.
  • Its Prepaid Assets was $19.8 million in Q3 2025, compared to $16.3 million in Q2 2025 and $16.0 million in Q1 2025.